Health ❯ Healthcare ❯ Pharmaceuticals

Cancer Treatment

Breast Cancer Immunotherapy Multiple Myeloma Clinical Trials Non-Small Cell Lung Cancer Lung Cancer Bladder Cancer Small Cell Lung Cancer Drug Development Prostate Cancer Mantle Cell Lymphoma Oncology Targeted Therapy Keytruda Follicular Lymphoma Gene Therapy Life-saving Drugs Lymphoma Medication Supply CAR T Cell Therapy Existing Drugs Ogsiveo 3SBio Licensing Deal Drug Pricing mRNA Therapies Tyrosine Kinase Inhibitors Opdivo Chemotherapy Pembrolizumab Head and Neck Cancer mRNA Technology Gastrointestinal Cancer Menin Inhibitors Triple-Negative Breast Cancer Trastuzumab Deruxtecan PARP Inhibitors Monoclonal Antibodies Cutaneous Squamous Cell Carcinoma Libtayo Basal Cell Carcinoma Oncology Research ALK-positive NSCLC Radioligand Therapy Acute Myeloid Leukemia Colorectal Cancer HER2-positive Breast Cancer EGFR-mutated Non-small Cell Lung Cancer Opioid Treatment mRNA Therapy Radiation Therapy Amtagvi Springworks Therapeutics

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

The one‑minute injection shifts care toward simpler outpatient visits under an approval requiring confirmatory trials.

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

FDA Accepts Sonrotoclax NDA, Grants Priority Review for Relapsed Mantle Cell Lymphoma

FDA Approves Perioperative Keytruda–Padcev for Cisplatin‑Ineligible Muscle‑Invasive Bladder Cancer

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

Merck Beats in Q3 on Keytruda, Narrows 2025 Outlook as Gardasil Slumps in China

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of High‑Risk CSCC

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

FDA Approves Keytruda QLEX, a Rapid Subcutaneous Option for Most Adult Solid Tumor Uses